CA9 and nonpapillary renal cell carcinoma: Modest responses were also reported in clinical trials with the anti-CAIX monoclonal antibody G250 (13), but no improvement in survival compared with placebo was observed in a phase 3 adjuvant trial in patients with high-risk ccRCC (23).